All In Biotech

Drug Trial Radar · NCT00345683

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.

Single-blind, Randomized, Controlled, Multinational Study for the Evaluation of Safety of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to Monovalent Hib Control Vaccine in Healthy Infants at 2, 4, 6, and 12 to 15 Months of Age.

Last checked: Nov 19, 2026Latest source record: Nov 29, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 4,021 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,021

Actual

Start

Jul 2007

Primary completion

Sep 2008

Study completion Nov 2008

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jun 28, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (care provider)
Primary purpose
Prevention
Who can join
All sexes, from 12 months, up to 15 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The booster phase of the study will evaluate the safety of Hib-MenCY-TT vaccine compared to a control group receiving licensed Hib conjugate vaccine at 12 to 15 months of age. This protocol posting deals with objectives \& outcome measures of the booster phase. The objectives \& outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT00345579). No new recruitment will take place during this booster phase of the study. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Conditions

  • Haemophilus Influenzae Type b
  • Neisseria Meningitidis

Interventions

  • GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (792014)Biological

    Booster dose by intramuscular injection

  • PedvaxHIBBiological

    Booster dose by intramuscular injection

  • PrevnarBiological

    Booster dose by intramuscular injection

  • M-M-R IIBiological

    Single dose by subcutaneous injection

  • VarivaxBiological

    Single dose by subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects Reporting Serious Adverse Events (SAEs)Time frame: From fourth dose up to Day 30 after fourth dose vaccination (from study Month 10-13 up to study Month 11-14)
  2. Number of Subjects Reporting New Onset of Chronic Illnesses (NOCIs)Time frame: From fourth dose up to Day 30 after fourth dose vaccination (from study Month 10-13 up to study Month 11-14)
  3. Number of Subjects Reporting RashTime frame: From fourth dose up to Day 30 after fourth dose vaccination (from study Month 10-13 up to study Month 11-14)
  4. Number of Subjects Reporting Adverse Events Resulting in Emergency Room (ER) VisitsTime frame: From fourth dose up to Day 30 after fourth dose vaccination (from study Month 10-13 up to study Month 11-14)
  5. Number of Subjects With Serious Adverse Events (SAEs)Time frame: From fourth dose through the end of the 6-month safety follow-up of the fourth dose phase (from study Month 10-13 up to study Month 16-19)
  6. Number of Subjects With New Onset of Chronic Illnesses (NOCIs)Time frame: From fourth dose through the end of the 6-month safety follow-up of the fourth dose phase (from study Month 10-13 up to study Month 16-19)
  7. Number of Subjects With RashTime frame: From fourth dose through the end of the 6-month safety follow-up of the fourth dose phase (from study Month 10-13 up to study Month 16-19)
  8. Number of Subjects With Adverse Events Resulting in Emergency Room (ER) VisitsTime frame: From fourth dose through the end of the 6-month safety follow-up of the fourth dose phase (from study Month 10-13 up to study Month 16-19)

Locations

57 sites in 2 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Benton, Arkansas

  • GSK Investigational Site

    Jonesboro, Arkansas

  • GSK Investigational Site

    Little Rock, Arkansas

  • GSK Investigational Site

    Fountain Valley, California

  • GSK Investigational Site

    Fresno, California

  • GSK Investigational Site

    Fresno, California

  • GSK Investigational Site

    Madera, California

  • GSK Investigational Site

    Slinas, California

  • GSK Investigational Site

    West Covina, California

  • GSK Investigational Site

    Boulder, Colorado

  • GSK Investigational Site

    Longmont, Colorado

  • GSK Investigational Site

    Plantation, Florida

  • GSK Investigational Site

    Nampa, Idaho

  • GSK Investigational Site

    Waukee, Iowa

  • GSK Investigational Site

    West Desmoines, Iowa

  • GSK Investigational Site

    Bardstown, Kentucky

  • GSK Investigational Site

    Lexington, Kentucky

  • GSK Investigational Site

    Bossier City, Louisiana

  • GSK Investigational Site

    Boston, Massachusetts

  • GSK Investigational Site

    Nies, Michigan

  • GSK Investigational Site

    Portage, Michigan

  • GSK Investigational Site

    Stevensville, Michigan

  • GSK Investigational Site

    Saint Paul, Minnesota

  • GSK Investigational Site

    Las Vegas, Nevada

  • GSK Investigational Site

    Ithaca, New York

  • GSK Investigational Site

    New Hartford, New York

  • GSK Investigational Site

    Syracuse, New York

  • GSK Investigational Site

    Raleigh, North Carolina

  • GSK Investigational Site

    Boardman, Ohio

  • GSK Investigational Site

    Canton, Ohio

  • GSK Investigational Site

    Cleveland, Ohio

  • GSK Investigational Site

    North Canton, Ohio

  • GSK Investigational Site

    South Euclid, Ohio

  • GSK Investigational Site

    Erie, Pennsylvania

  • GSK Investigational Site

    Greenville, Pennsylvania

  • GSK Investigational Site

    Pittsburgh, Pennsylvania

  • GSK Investigational Site

    Pittsburgh, Pennsylvania

  • GSK Investigational Site

    Pittsburgh, Pennsylvania

Showing 40 of 57 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.